Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's disease (stage II and III of H&Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.
Negrotti
A
A
Istituto di Neurologia, Università di Parma, Italy.
Bizzarri
G
G
Calzetti
S
S
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001971:Bromocriptine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013375:Substance Withdrawal Syndrome
D000978:Antiparkinson Agents; D012642:Selegiline; D001971:Bromocriptine